Total cancer care moffit cancer center
GO
 

Rami S. Komrokji, MD

Where You Are:

Rami S. Komrokji, MD

Hematology

For Consultation Requests or Referrals: (813) 745-8986

 
 

BOARD CERTIFICATION:
          •  Internal Medicine - Medical Oncology
          •  Internal Medicine - Hematology

FELLOWSHIP:
          •  Strong Memorial Hospital, University of Rochester - Hematology/Oncology

RESIDENCY:
          •  Case Western University, St. Vincent Program - Internal Medicine

MEDICAL SCHOOL:
          •  Jordan University School of Medicine - MD

  • Ad?s L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, Maciejewski JP, Dreyfus F, List AF, Fenaux P, Komrokji RS. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013 Jun;37(6):609-613. Pubmedid: 23415110.

  • Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res. 2013 May;37(5):510-515. Pubmedid: 23332452.

  • Zeidan AM, Smith BD, Komrokji RS, Gore SD. Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS). Am J Med. 2013 Apr;126(4):e25. Pubmedid: 23507216.

  • Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Apr. Pubmedid: 23632888.

  • Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 2013 Apr;27(4):897-906. Pubmedid: 23072779.

  • Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr;21(4):1097-1103. Pubmedid: 23179489.

  • Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Apr. Pubmedid: 23605934.

  • Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk Res. 2013 Mar;37(3):300-304. Pubmedid: 23273539.

  • Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma. 2013 Jan. Pubmedid: 23278639.

  • Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec;120(25):4945-4951. Pubmedid: 22915641. Pmcid: PMC3525020.

  • Komrokji R, Verstovsek S. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Rev Hematol. 2012 Dec;5(6):631-641. Pubmedid: 23216593.

  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.

  • Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012 Oct;19(4 Suppl):4-15. Pubmedid: 23042420.

  • Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct;120(17):3419-3424. Pubmedid: 22936658.

  • Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012 Sep;189(6):3198-3208. Pubmedid: 22875800. Pmcid: PMC3436939.

  • Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May;118(10):2659-2664. Pubmedid: 21956402.

  • Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012 Apr;118(8):2138-2147. Pubmedid: 21887679.

  • Duong VH, Komrokji RS, List AF. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Ther Adv Hematol. 2012 Apr;3(2):105-116. Pubmedid: 23556117. Pmcid: PMC3573434.

  • Carballido E, Veliz M, Komrokji R, Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control. 2012 Jan;19(1):54-67. Pubmedid: 22143062.

  • Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012 Jan;36(1):72-80. Pubmedid: 21782240.

  • Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes. Curr Pharm Des. 2012;18(22):3198-3203. Pubmedid: 22571699.

  • Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. Curr Treat Options Oncol. 2011 Dec;12(4):354-368. Pubmedid: 21964863.

  • Komrokji RS, List AF. Role of lenalidomide in the treatment of myelodysplastic syndromes. Semin Oncol. 2011 Oct;38(5):648-657. Pubmedid: 21943671.

  • Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Mel?ndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leuk Lymphoma. 2011 Aug;52(8):1528-1536. Pubmedid: 21635204.

  • Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun;35(6):e81-e83. Pubmedid: 21232795.

  • Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-260. Pubmedid: 21658652.

  • Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndromes:the art and evidence. Curr Hematol Malig Rep. 2011 Jun;6(2):145-153. Pubmedid: 21442178.

  • Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF, Komrokji R. Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. J Clin Oncol. 2011 May;29(15):e434-e436. Pubmedid: 21149648.

  • Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011 Apr;117(7):1463-1469. Pubmedid: 21425147.

  • Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar;35(3):301-304. Pubmedid: 21109304.

  • Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2011 Mar;17(3):384-393. Pubmedid: 20655389.

  • Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011 Feb;4(1):61-69. Pubmedid: 21322779.

  • Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2011 Jan;9(1):30-56. Pubmedid: 21233243.

  • Ortega J, Komrokji R, List AF. The hematopoietic growth factors in the myelodysplastic syndromes. Cancer Treat Res. 2011;157:363-382. Pubmedid: 21052966.

  • Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. Am J Hematol. 2010 Nov;85(11):904-907. Pubmedid: 20890908.

  • Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2010 Nov. Pubmedid: 21061347.

  • Khan AM, Komrokji RS, Haddad RY. Myelodysplastic syndromes: what a primary care physician needs to know. Dis Mon. 2010 Aug;56(8):468-478. Pubmedid: 20800756.

  • Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am. 2010 Apr;24(2):377-388. Pubmedid: 20359632.

  • Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am. 2010 Apr;24(2):443-457. Pubmedid: 20359636.

  • Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 2010 Feb;95(2):340-342. Pubmedid: 19850902. Pmcid: PMC2817042.

  • Komrokji RS, Lancet JE, List AF. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?. Curr Hematol Malig Rep. 2010 Jan;5(1):9-14. Pubmedid: 20425391.

  • Komrokji RS, Matacia-Murphy GM, Al Ali NH, Beg MS, Safa MM, Rollison DE, List AF. Outcome of patients with myelodysplastic syndromes in the Veterans Administration population. Leuk Res. 2010 Jan;34(1):59-62. Pubmedid: 19368972.

  • Ahmed F, Osman N, Lucas F, Neff G, Smolarek T, Bennett JM, Komrokji RS. Therapy related CMML: a case report and review of the literature. Int J Hematol. 2009 Jun;89(5):699-703. Pubmedid: 19430863.

  • Walker AR, Komrokji RJ, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec;32(12):1830-1836. Pubmedid: 18571721.

  • Beg M, Komrokji R, Ahmed K, Safa M. Oxaliplatin-induced immune mediated thrombocytopenia. Cancer Chemother Pharmacol. 2008 Oct;62(5):925-927. Pubmedid: 18204841.

  • Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer. 2007 Apr;109(8):1471-1477. Pubmedid: 17342768.

  • Komrokji R, Bennett J. Evolving classifications of the myelodysplastic syndromes. Curr Opin Hematol. 2007 Mar;14(2):98-105. Pubmedid: 17255786.

  • Komrokji R. Myelodysplastic syndromes: a view from where the sun rises and where the sun sets. Leuk Res. 2006 Sep;30(9):1067-1068. Pubmedid: 16723153.

  • Komrokji R, Uppal N, Khorana A, Lyman G, Kaplan K, Fisher R, Francis C. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006 Jun;47(6):1029-1033. Pubmedid: 16840193.

  • Komrokji RS, Bennett JM. Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification. Curr Hematol Malig Rep. 2006 Mar;1(1):9-15. Pubmedid: 20425325.

  • Komrokji R, Oliva J, Zand M, Felgar R, Abboud C. Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol. 2005 Jul;79(3):211-215. Pubmedid: 15981226.

  • Komrokji R, Bennett J. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes. Curr Hematol Rep. 2005 May;4(3):175-181. Pubmedid: 15865868.

  • Bennett J, Komrokji R. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005;10:258-269. Pubmedid: 16188686.

  • Komrokji R, Lyman G. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther. 2004 Dec;4(12):1897-1910. Pubmedid: 15571452.

  • Komrokji R, Ifthikharuddin J, Felgar R, Abboud C, Wedow L, Connaughton A, Bennett J. Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature review. Am J Hematol. 2004 Aug;76(4):389-394. Pubmedid: 15282676.

  • Komrokji R, Bennett J. The myelodysplastic syndromes: classification and prognosis. Curr Hematol Rep. 2003 May;2(3):179-185. Pubmedid: 12901338.

  • Nahleh Z, Komrokji R, Jazieh A, Benedetti J, Sparks D. Cancer research training: the Southwest Oncology Group young investigator training program (YITP). J Cancer Educ. 2006 Sum;21(2):77-79. Pubmedid: 17020517.

Myelodysplastic syndromes (MDS), Acute Myeloid leukemia (AML), Non-Hodgkin's Lymphoma, Hodgkin's Disease.

Find a Doctor Schedule an Appointment Login to Patient Portal Outcomes Make a Donation
 
 
TOOLS:   Font Size
 |  Site Map  |  Privacy Policy  |  Terms and Conditions  |  Staff Login